GREY:SBIYF - Post by User
Comment by
Everswanon Jun 19, 2009 4:48pm
650 Views
Post# 16085374
RE: RE: RE: 1 yr of cash at quite a cost
RE: RE: RE: 1 yr of cash at quite a cost
Well, SBS did not pull out of the deal. Mannkind did.
For plant based insulin to overtake competition, it has to be much cheaper.
According to the company, it is 30% cheaper to make.
Maybe they can improve on that number with the Hydresia experience.
Botaneco has 1 major hydresia client (Burt's Bee a subsidiary of Clorox) and 29 smallers clients.
They were supposed to announced a second big customer, but the deal seems to have sizzled since.
Right now Botaneco is still burning cash. I hope it will turn cash positive and it will contribute to sembiosys.
We need something like 30-45 millions for PIII trial (insulin) and PI trial (API milano).
Next 12 months will be rather boring as we wait for FDA to give green light for PIII insulin and PI api.
Look for the 2nd large Hydresia customer, that will be a turning point...